Literature DB >> 22198210

A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.

Ombretta Melaiu1, Alfonso Cristaudo2, Erika Melissari3, Manuela Di Russo4, Alessandra Bonotti5, Rossella Bruno6, Rudy Foddis7, Federica Gemignani8, Silvia Pellegrini9, Stefano Landi10.   

Abstract

Malignant pleural mesothelioma (MPM), a cancer of the serosal pleural cavities, is one of the most aggressive human tumors. In order to identify genes crucial for the onset and progression of MPM, we performed an extensive literature review focused on transcriptome studies (RTS). In this kind of studies a great number of transcripts are analyzed without formulating any a priori hypothesis, thus preventing any bias coming from previously established knowledge that could lead to an over-representation of specific genes. Each study was thoroughly analyzed paying particular attention to: (i) the employed microarray platform, (ii) the number and type of samples, (iii) the fold-change, and (iv) the statistical significance of deregulated genes. We also performed data mining (DM) on MPM using three different tools (Coremine, SNPs3D, and GeneProspector). Results from RTS and DM were compared in order to restrict the number of genes potentially deregulated in MPM. Our main requirement for a gene to be a "mesothelioma gene" (MG) is to be reproducibly deregulated among independent studies and confirmed by DM. A list of MGs was thus produced, including PTGS2, BIRC5, ASS1, JUNB, MCM2, AURKA, FGF2, MKI67, CAV1, SFRP1, CCNB1, CDK4, and MSLN that might represent potential novel biomarkers or therapeutic targets for MPM. Moreover, it was found a sub-group of MGs including ASS1, JUNB, PTGS2, EEF2, SULF1, TOP2A, AURKA, BIRC5, CAV1, IFITM1, PCNA, and PKM2 that could explain, at least in part, the mechanisms of resistance to cisplatin, one first-line chemotherapeutic drug used for the disease. Finally, the pathway analysis showed that co-regulation networks related to the cross-talk between MPM and its micro-environment, in particular involving the adhesion molecules, integrins, and cytokines, might have an important role in MPM. Future studies are warranted to better characterize the role played by these genes in MPM.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198210     DOI: 10.1016/j.mrrev.2011.12.003

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  20 in total

1.  Mitogen-activated protein kinase signaling controls basal and oncostatin M-mediated JUNB gene expression.

Authors:  Mellissa J Hicks; Qiuping Hu; Erin Macrae; James DeWille
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

Review 2.  Biomarkers in the prevention and follow-up of workers exposed to asbestos.

Authors:  Rudy Foddis; Alessandra Bonotti; Stefano Landi; Poupak Fallahi; Giovanni Guglielmi; Alfonso Cristaudo
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 3.  Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

Authors:  Elisa Barone; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

4.  Alisertib induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells.

Authors:  Zheng Liu; Feng Wang; Zhi-Wei Zhou; He-Chun Xia; Xin-Yu Wang; Yin-Xue Yang; Zhi-Xu He; Tao Sun; Shu-Feng Zhou
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

5.  Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Authors:  Deepa Magge; Mazen S Zenati; Frances Austin; Arun Mavanur; Magesh Sathaiah; Lekshmi Ramalingam; Heather Jones; Amer H Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-12-10       Impact factor: 5.344

6.  A SILAC-based proteomics elicits the molecular interactome of alisertib (MLN8237) in human erythroleukemia K562 cells.

Authors:  Li-Ping Shu; Zhi-Wei Zhou; Dan Zi; Zhi-Xu He; Shu-Feng Zhou
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

Review 7.  The Molecular Basis of Malignant Pleural Mesothelioma.

Authors:  Benjamin Wadowski; Assunta De Rienzo; Raphael Bueno
Journal:  Thorac Surg Clin       Date:  2020-09-12       Impact factor: 1.750

Review 8.  Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.

Authors:  Melissa M Phillips; Michael T Sheaff; Peter W Szlosarek
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

9.  Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

Authors:  Giuseppe Matullo; Simonetta Guarrera; Marta Betti; Giovanni Fiorito; Daniela Ferrante; Floriana Voglino; Gemma Cadby; Cornelia Di Gaetano; Fabio Rosa; Alessia Russo; Ari Hirvonen; Elisabetta Casalone; Sara Tunesi; Marina Padoan; Mara Giordano; Anna Aspesi; Caterina Casadio; Francesco Ardissone; Enrico Ruffini; Pier Giacomo Betta; Roberta Libener; Roberto Guaschino; Ezio Piccolini; Monica Neri; Arthur W B Musk; Nicholas H de Klerk; Jennie Hui; John Beilby; Alan L James; Jenette Creaney; Bruce W Robinson; Sutapa Mukherjee; Lyle J Palmer; Dario Mirabelli; Donatella Ugolini; Stefano Bonassi; Corrado Magnani; Irma Dianzani
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

10.  Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.

Authors:  Feng Wang; Hai Li; Xiao-Gang Yan; Zhi-Wei Zhou; Zhi-Gang Yi; Zhi-Xu He; Shu-Ting Pan; Yin-Xue Yang; Zuo-Zheng Wang; Xueji Zhang; Tianxing Yang; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-01-17       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.